Shares of Pulse Biosciences Inc. (NASDAQ: PLSE) surged 6.10% on October 30, 2024, following the company's release of its third-quarter 2024 financial results and a series of positive business updates.
The bioelectric medicine company reported a net loss of $12.7 million for the third quarter, but investors seemed to focus on the progress made in the development of its novel Nanosecond Pulsed Field Ablation (nsPFA) technology and the potential it holds across various applications.
One of the key highlights was the appointment of Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology and the addition of Dr. Andrea Natale as a medical advisor. Both renowned physicians will contribute their expertise in supporting the clinical development of Pulse Biosciences' nano-PFA 360 Cardiac Catheter for the treatment of atrial fibrillation.
Furthermore, the company provided updates on the progress of clinical trials for its nsPFA technology. Pulse Biosciences expects to commence pivotal trials in the U.S. for its Percutaneous Electrode System for benign thyroid nodules, its Cardiac Surgical System for atrial fibrillation treatment, and its 360 Cardiac Catheter, all in mid-2025. These milestones are seen as crucial steps towards potential commercialization of the company's innovative technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.